CAS: 160337-95-1; Basaglar
化学文摘社编号160337-95-1确定了这种特定的胰岛素变异物,它与其他胰岛素配方相比可能有不同的致癌性.其稳定性,溶性以及生物利用率对于其作为治疗剂的有效性至关重要.
- 英文名称Basaglar
- 中文名称甘精胰岛素
- IUPAC名称(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-(carboxymethylcarbamoyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
- CAS编号160337-95-1
- MFCD编号:MFCD09260251
- EINECS号:810-906-5
- 分子式:C267H404N72O78S6分子量:6062.89026
- 产品CID: 806464
- 产品分类原料药 → 激素及调节内分泌功能类药 → 胰腺激素及其它调节血糖药
MSDS等安全信息
欧盟法规
C&L通报合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2905122000-异丙醇
2912110000-甲醛
2912120000-乙醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
参考文献:10.1007/s00125-010-1678-z
摘要:Wägner AM, Mauricio D. Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions Diabetologia. 2010 May;53(5):1004–5; author reply 1006. doi: 10.1007/s00125-010-1678-z.
参考文献:10.1089/dia.2011.0050
摘要:DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of Exenatide in Poly-(
参考文献:10.1186/1475-2840-10-65
摘要:Hanefeld M, Pfützner A, Forst T, Kleine I, Fuchs W. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovascular Diabetology. 2011 Jul 14;10(1):65. doi: 10.1186/1475-2840-10-65.
参考文献:10.1007/s12672-010-0020-z
摘要:Nagel JM, Staffa J, Renner-Müller I, Horst D, Vogeser M, Langkamp M, Hoeflich A, Göke B, Kolligs FT, Mantzoros CS. Insulin Glargine and NPH Insulin Increase to a Similar Degree Epithelial Cell Proliferation and Aberrant Crypt Foci Formation in Colons of Diabetic Mice. Discover Oncology. 2010 Aug 05;1(6):320–30. doi: 10.1007/s12672-010-0020-z.
摘要:Petznick A. Insulin management of type 2 diabetes mellitus. Am Fam Physician. 2011 Jul 15;84(2):183–90.
📝 需求与反馈
尽可能描述清楚需求与问题信息
